具有抗过敏作用的独特化合物:通过KIRA6抑制Lyn激酶活性
Goshi Matsushima1, Yuri Matsui1, Hanano Okamoto1
1Department of Pharmacotherapy, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Frontiers in pharmacology
|August 11, 2025
概括
这项研究表明,KIRA6,一种需要伊诺西的酶1α (IRE1α) 抑制剂,通过抑制独立于IRE1α的Lyn激酶活性来预防过敏反应. 这一发现为过敏性疾病提供了一个新的治疗策略.
科学领域:
- 免疫学 免疫学 免疫学
- 细胞生物学 细胞生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 乳腺细胞和基细胞是过敏反应的关键参与者,通过IgE受体激活来调解炎症.
- 抗原诱导的激活导致释放和媒介释放,涉及像Lyn和Syk.这样的氨酸激酶.
- 细胞内膜网膜 (ER) 压力分子,如IRE1α,在巨细胞激活中的作用尚未完全理解.
研究的目的:
- 为了研究与ER压力相关的分子在质细胞和基细胞激活中的参与.
- 探索IRE1α抑制剂在过敏性疾病中的治疗潜力.
主要方法:
- 利用抗原诱导激活模型在老鼠基白血病 (RBL) - 2H3细胞,骨髓衍生性巨细胞 (BMMCs),人类基细胞和人类巨细胞中.
- 采用了IRE1α抑制剂KIRA6和IRE1α淘汰模型.
- 评估了促炎媒介的释放和Lyn和Syk氨酸激酶的激活.
- 在体内评估KIRA6的抗过敏作用.
主要成果:
- 抗原刺激激活了IRE1α-splicedX盒结合蛋白1 (sXBP1) 途径在巨细胞中.
- 低剂量KIRA6 (<1μM) 抑制了各种细胞类型中介体释放.
- 令人惊的是,IRE1α淘汰并没有抑制抗原诱导的介质释放.
- KIRA6抑制了Lyn酶的活性,因此阻断了Syk的激活和下游介质的释放.
- KIRA6在体内表现出抗过敏作用.
结论:
- 这项研究发现了一种新的机制,即KIRA6通过准独立于IRE1α的Lyn激酶活性来抑制过敏反应.
- KIRA6显示出作为治疗过敏疾病的治疗剂的前景.
- 这些发现挑战了 IRE1α 在抗原诱导的巨细胞媒介释放中的直接作用.
相关概念视频
02:34Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
01:19Antiasthma Drugs: Leukotriene Modifiers
470
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
470
01:27Allergic Drug Reactions
979
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
979
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
459
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
459